HER2 as a Potential Drug Target and its Prevalence in GI Malignancies
An experienced oncologist discusses the role of HER2 in GI malignancies and the applicability of the existing body of research concerning HER2 in breast cancer.
EP: 1.Recent Advancements and Current Areas of Focus in the Treatment of mCRC
Now Viewing
EP: 2.HER2 as a Potential Drug Target and its Prevalence in GI Malignancies
EP: 3.Biomarker Testing and Next-Generation Sequencing Inform Modern Treatment Strategies for mCRC
EP: 4.MOUNTAINEER Trial: Rationale, Results and Clinical Implications
EP: 5.Promising Early Data from GI Malignancy Trials
Related Videos
Related Content
